RANKL/RANK pathway abrogates cetuximab sensitivity in gastric cancer cells via activation of EGFR and c-Src

Overexpression of EGFR is commonly seen in gastric cancer (GC). However, patients with GC show resistance to anti-EGFR treatments. RAS mutations are rare in GC and cannot explain de novo resistance to EGFR treatments. Therefore, it is particularly important to explore the mechanisms of resistance to...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Onco Targets Ther
Main Authors: Zhang, Xiaomeng, Song, Yongxi, Song, Na, Zhang, Ye, Zhang, Lingyun, Wang, Yan, Wang, Zhenning, Qu, Xiujuan, Liu, Yunpeng
Format: Artigo
Jezik:Inglês
Izdano: Dove Medical Press 2017
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5229171/
https://ncbi.nlm.nih.gov/pubmed/28123301
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S110918
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki